Full-Time

Director – Global Medical Affairs

Flu Vaccines

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

70/30 work model requires 70% in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Advanced degree required (PharmD, PhD, Master’s in Biotechnology, Life Sciences or equivalent).
  • 8+ years of experience in medical affairs within the pharmaceutical or biotechnology industry, including 3+ years focused on vaccines.
  • Strong project management skills with the ability to manage multiple projects simultaneously.
  • Excellent written and verbal communication skills with the ability to present complex scientific information clearly and concisely.
  • Strong interpersonal skills with experience building relationships with KOLs and external stakeholders.
  • Proven track record of synthesizing key scientific messages with accuracy and agility, particularly in high-stakes environments related to public health and vaccine strategy.
Responsibilities
  • Develop and execute the global medical strategy for Moderna’s Flu vaccines in close collaboration with the portfolio GMAL, ensuring alignment with broader portfolio objectives and business goals.
  • Collaborate with and guide cross-functional teams to ensure that medical affairs activities are strategically integrated and operationally executed in line with the overall product strategy.
  • Oversee the planning and execution of clinical studies, real-world evidence generation, and other data generation activities related to the Flu vaccines.
  • Align data dissemination strategies for Flu vaccines with portfolio objectives, working closely with the Scientific Communications team.
  • Communicate complex scientific information effectively across all levels of the organization, including executive leadership and external stakeholders.
  • Engage strategically with key opinion leaders (KOLs), medical societies, and other external stakeholders to gather insights and support the global medical strategy for Flu vaccines. Represent Moderna at external meetings, conferences, PHDM engagements and advisory boards related to the Flu vaccines.
  • Oversee the development of global medical education initiatives, ensuring alignment with strategic objectives in collaboration with the Scientific Communications team.
  • Ensure compliance with global and local regulations, industry guidelines, and corporate policies for all medical affairs activities related to the respiratory vaccines.
  • Work closely with regional and market teams to align global strategies with local market needs and regulatory requirements, ensuring successful implementation of medical affairs activities globally.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?